Strides Pharma Science Limited (STAR) - Net Assets
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has net assets worth Rs28.03 Billion INR (≈ $303.11 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs65.21 Billion ≈ $705.18 Million USD) and total liabilities (Rs37.18 Billion ≈ $402.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check STAR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs28.03 Billion |
| % of Total Assets | 42.98% |
| Annual Growth Rate | 13.17% |
| 5-Year Change | -8.09% |
| 10-Year Change | -11.0% |
| Growth Volatility | 46.85 |
Strides Pharma Science Limited - Net Assets Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's net assets have evolved over time, based on quarterly financial data. Also explore Strides Pharma Science Limited assets under control for the complete picture of this company's asset base.
Annual Net Assets for Strides Pharma Science Limited (2005–2025)
The table below shows the annual net assets of Strides Pharma Science Limited from 2005 to 2025. For live valuation and market cap data, see market value of Strides Pharma Science Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs25.86 Billion ≈ $279.72 Million |
+24.85% |
| 2024-03-31 | Rs20.72 Billion ≈ $224.05 Million |
-4.66% |
| 2023-03-31 | Rs21.73 Billion ≈ $234.99 Million |
-8.83% |
| 2022-03-31 | Rs23.83 Billion ≈ $257.75 Million |
-15.31% |
| 2021-03-31 | Rs28.14 Billion ≈ $304.32 Million |
+8.45% |
| 2020-03-31 | Rs25.95 Billion ≈ $280.60 Million |
-7.39% |
| 2019-03-31 | Rs28.02 Billion ≈ $302.99 Million |
+7.38% |
| 2018-03-31 | Rs26.09 Billion ≈ $282.18 Million |
-9.23% |
| 2017-03-31 | Rs28.74 Billion ≈ $310.86 Million |
-1.09% |
| 2016-03-31 | Rs29.06 Billion ≈ $314.27 Million |
+149.73% |
| 2015-03-31 | Rs11.64 Billion ≈ $125.84 Million |
+7.50% |
| 2014-03-31 | Rs10.82 Billion ≈ $117.07 Million |
-48.41% |
| 2013-03-31 | Rs20.98 Billion ≈ $226.90 Million |
+47.97% |
| 2012-03-31 | Rs14.18 Billion ≈ $153.34 Million |
-8.83% |
| 2011-03-31 | Rs15.55 Billion ≈ $168.20 Million |
+42.74% |
| 2010-03-31 | Rs10.90 Billion ≈ $117.83 Million |
+82.91% |
| 2009-03-31 | Rs5.96 Billion ≈ $64.42 Million |
+102.95% |
| 2008-03-31 | Rs2.94 Billion ≈ $31.74 Million |
-31.86% |
| 2007-03-31 | Rs4.31 Billion ≈ $46.59 Million |
+24.30% |
| 2006-03-31 | Rs3.47 Billion ≈ $37.48 Million |
+59.19% |
| 2005-03-31 | Rs2.18 Billion ≈ $23.54 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Strides Pharma Science Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 458919000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs4.59 Billion | 17.98% |
| Common Stock | Rs921.63 Million | 3.61% |
| Other Comprehensive Income | Rs4.91 Billion | 19.25% |
| Other Components | Rs15.09 Billion | 59.15% |
| Total Equity | Rs25.52 Billion | 100.00% |
Strides Pharma Science Limited Competitors by Market Cap
The table below lists competitors of Strides Pharma Science Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
$1.03 Billion |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
$1.03 Billion |
|
Ina Invest Holding AG
SW:INA
|
$1.03 Billion |
|
Chengdu Hongqi Chain Co Ltd
SHE:002697
|
$1.03 Billion |
|
Sinoseal Holding Co Ltd
SHE:300470
|
$1.03 Billion |
|
NeoGenomics Inc
NASDAQ:NEO
|
$1.03 Billion |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
$1.03 Billion |
|
Sinodata Co Ltd
SHE:002657
|
$1.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Strides Pharma Science Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,255,630,000 to 25,518,310,000, a change of 4,262,680,000 (20.1%).
- Net income of 35,934,550,000 contributed positively to equity growth.
- Dividend payments of 229,900,000 reduced retained earnings.
- New share issuances of 61,020,000 increased equity.
- Other comprehensive income decreased equity by 35,460,000.
- Other factors decreased equity by 31,467,530,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs35.93 Billion | +140.82% |
| Dividends Paid | Rs229.90 Million | -0.9% |
| Share Issuances | Rs61.02 Million | +0.24% |
| Other Comprehensive Income | Rs-35.46 Million | -0.14% |
| Other Changes | Rs-31.47 Billion | -123.31% |
| Total Change | Rs- | 20.05% |
Book Value vs Market Value Analysis
This analysis compares Strides Pharma Science Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 44.44x to 3.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs23.33 | Rs1036.80 | x |
| 2006-03-31 | Rs34.66 | Rs1036.80 | x |
| 2007-03-31 | Rs42.22 | Rs1036.80 | x |
| 2008-03-31 | Rs30.89 | Rs1036.80 | x |
| 2009-03-31 | Rs46.39 | Rs1036.80 | x |
| 2010-03-31 | Rs92.82 | Rs1036.80 | x |
| 2011-03-31 | Rs143.26 | Rs1036.80 | x |
| 2012-03-31 | Rs153.17 | Rs1036.80 | x |
| 2013-03-31 | Rs226.30 | Rs1036.80 | x |
| 2014-03-31 | Rs112.45 | Rs1036.80 | x |
| 2015-03-31 | Rs127.87 | Rs1036.80 | x |
| 2016-03-31 | Rs319.77 | Rs1036.80 | x |
| 2017-03-31 | Rs302.71 | Rs1036.80 | x |
| 2018-03-31 | Rs274.13 | Rs1036.80 | x |
| 2019-03-31 | Rs295.70 | Rs1036.80 | x |
| 2020-03-31 | Rs282.13 | Rs1036.80 | x |
| 2021-03-31 | Rs309.52 | Rs1036.80 | x |
| 2022-03-31 | Rs262.87 | Rs1036.80 | x |
| 2023-03-31 | Rs245.57 | Rs1036.80 | x |
| 2024-03-31 | Rs233.25 | Rs1036.80 | x |
| 2025-03-31 | Rs277.31 | Rs1036.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Strides Pharma Science Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 140.82%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 77.71%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 2.37x
- Recent ROE (140.82%) is above the historical average (17.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 21.06% | 9.81% | 0.82x | 2.62x | Rs231.08 Million |
| 2006 | 15.65% | 9.27% | 0.56x | 3.02x | Rs175.26 Million |
| 2007 | 10.64% | 5.41% | 0.61x | 3.25x | Rs24.23 Million |
| 2008 | -18.12% | -6.91% | 0.36x | 7.35x | Rs-777.80 Million |
| 2009 | 25.99% | 10.58% | 0.44x | 5.60x | Rs664.22 Million |
| 2010 | 13.20% | 8.41% | 0.40x | 3.89x | Rs265.76 Million |
| 2011 | 9.55% | 7.22% | 0.38x | 3.50x | Rs-58.31 Million |
| 2012 | 16.37% | 8.89% | 0.46x | 3.98x | Rs873.28 Million |
| 2013 | 41.76% | 38.39% | 0.46x | 2.37x | Rs6.44 Billion |
| 2014 | -18.54% | -17.40% | 0.51x | 2.08x | Rs-2.87 Billion |
| 2015 | 73.80% | 74.65% | 0.46x | 2.17x | Rs7.31 Billion |
| 2016 | 7.30% | 6.89% | 0.40x | 2.68x | Rs-773.83 Million |
| 2017 | 14.75% | 11.91% | 0.41x | 2.99x | Rs1.29 Billion |
| 2018 | 26.91% | 23.62% | 0.43x | 2.67x | Rs4.15 Billion |
| 2019 | 12.26% | 11.03% | 0.37x | 3.02x | Rs597.48 Million |
| 2020 | 1.44% | 1.37% | 0.43x | 2.43x | Rs-2.16 Billion |
| 2021 | 9.67% | 8.18% | 0.47x | 2.53x | Rs-92.24 Million |
| 2022 | -19.51% | -14.99% | 0.44x | 2.96x | Rs-6.96 Billion |
| 2023 | -10.00% | -6.03% | 0.55x | 3.00x | Rs-4.42 Billion |
| 2024 | -3.32% | -1.84% | 0.66x | 2.75x | Rs-2.83 Billion |
| 2025 | 140.82% | 77.71% | 0.76x | 2.37x | Rs33.38 Billion |
Industry Comparison
This section compares Strides Pharma Science Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Strides Pharma Science Limited (STAR) | Rs28.03 Billion | 21.06% | 1.33x | $1.03 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more